Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
about
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophreniaDose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.Placebo response in antipsychotic clinical trials: a meta-analysis.Almost all antipsychotics result in weight gain: a meta-analysis.Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.Antipsychotics inhibit glucose transport: Determination of olanzapine binding site in Staphylococcus epidermidis glucose/H(+) symporter.Comparative effectiveness research for antipsychotic medications: how much is enough?Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.Treatment strategies for dosing the second generation antipsychotics.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses.Pharmacogenetics of olanzapine metabolism.Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.Practical pharmacotherapy for acute schizophrenia patients.Antipsychotic Management of Schizoaffective Disorder: A Review.Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009).Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics.Integrating rare genetic variants into pharmacogenetic drug response predictions.Olanzapine: review of safety 2008
P2860
Q33816366-A1DB80BF-FD26-4CF3-BA31-F08B9C8FD999Q33821379-C503F261-1B6C-4D5C-816E-2E954076CE24Q33826250-7DBF2B86-50CA-4A97-A0C5-128322FDC53AQ34443837-A5A24057-3146-43C6-9962-9CD8A9B51BD2Q34661499-F038538B-BAAE-4976-928F-CE64804CC8F4Q35044176-3520416E-C3E2-40A0-8C47-D167E2720ED4Q35547830-8F5E09BE-DEC8-41F3-AC63-E2D84A075606Q35622982-A0E7482C-4CBC-40B4-A95E-9D340727781DQ35828559-D715D25E-E7BA-4AFD-BCF6-066936CD3AF1Q36325431-950508E6-A924-48A8-8841-C3715BD71AF5Q37532575-B1F31813-3EC3-4C18-8319-81606D7EC722Q37546091-EEE103CE-6DE5-4F0E-B76A-3203F3287BDFQ37760926-5F49A462-2602-47D0-A676-B8233DDD7AB5Q37852818-5951930B-10D5-4592-8D12-D0A7F6DCEEBDQ37863093-B4E921A9-104B-41A1-85D4-AC2E62250E40Q37896627-45500DB9-9B9C-4868-94DB-1038FDC79D30Q38068636-E1389F70-D0F8-425E-B68D-112318D42712Q38127716-4A4835A9-1507-48CB-88AD-409EB0D61712Q38203063-12872076-4A6C-4109-B5D9-2F4CCC0543B3Q38513767-6D0745CC-792B-4B8E-A5E7-F15D49F3601AQ38755501-DE8D3F08-5632-4D50-973B-2883F803C217Q42279135-C7AEBC7D-9F5B-44ED-AA0A-5842C96B266CQ45835487-0CC74683-0607-4204-9D05-B1867B231B08Q51369774-4C1CFA0C-3DD6-4352-9368-6EEF094E87DCQ51399602-BACA3205-BD6C-4B26-8E91-B83B16BD56A8Q54940794-F618DD54-6548-47F4-8076-C435A1994B17Q56791028-E23B1CD1-D93E-4278-96FF-C71A382FAC1E
P2860
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@ast
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@en
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@nl
type
label
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@ast
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@en
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@nl
prefLabel
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@ast
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@en
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@nl
P2093
P1476
Standard and higher dose of ol ...... ouble-blind, fixed-dose study.
@en
P2093
Bruce J Kinon
Daniel R Wilson
David H Adams
Herbert Y Meltzer
Hong Liu-Seifert
Jan Volavka
Jean-Pierre Lindenmayer
Jeffrey A Lieberman
Joseph P McEvoy
P304
P356
10.1097/JCP.0B013E31817E63A5
P407
P577
2008-08-01T00:00:00Z